1. Ashraf T, Hay J W, Pitt B, Wittels E, Crouse J, Davidson M, Furberg C D, Radican L. Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease. American Journal of Cardiology 1996;78(4):409-414.
2. Korman L, Borysiuk L. Replacing lovastatin with pravastatin: effect on serum lipids and costs. American Journal of Health-System Pharmacy 1995;52(10):1078-1082.
3. Muls E, Vanganse E, Closon M C. Cost-effectiveness of pravastatin in secondary prevention of coronary heart disease: comparison between Belgium and the United States of a projected risk model. Atherosclerosis 1998;137(Supplement S):S111-S116.
4. Smart A J, Walters L. Pharmaco-economic assessment of the HMG-CoA reductase inhibitors. South African Medical Journal 1994;84(12): 834-837.